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Abstract 
Artificial Intelligence (AI) ability of self-learning and adaptation has challenged the medical device regulation in overseeing the safety and effectiveness 
of medical devices. Thus, this research aims to evaluate the adequacy of the pre-market requirements under the Medical Device Act 2012 in governing 
AI modification. Employing the doctrinal research methodology, systematic means of legal reasoning pertinent to AI for healthcare applications are 
produced. An effective medical device regulation is pivotal to foster trustworthiness in the governance and adoption of AI. However, the research 
findings indicate the deficiency of the current conformity assessment for medical devices in addressing AI modifications. 
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1.0 Introduction 
Artificial Intelligence (AI) once seen as science fiction. Nevertheless, AI is now taking a leading role in revolutionising many industries, 
including the healthcare industry, capitalising on the vast swathes of data generated during healthcare delivery. Various medical 
specialities, ranging from radiology and oncology to ophthalmology and general medical decision-making, have integrated AI within 
general practices as this technology exponentially improves medical outcomes. Many challenges faced by health practitioners in 
providing treatment coverage to patients resolved by adopting AI-driven digital tools. Amongst these challenges are difficulty in handling 
explosions of digital data and the discovery of novel diseases. Able to replicate human cognitive functions, AI may perform as well, if 
not better than the healthcare practitioners, augmenting the healthcare practitioners’ efforts in, among others, making more accurate 
diagnoses, identifying at-risk populations, managing and better understanding patients’ responses to medicines and treatment protocols. 
As healthcare practitioners are supplied with a massive amount of data on patients within the healthcare setting, AI can trace the most 
relevant clinical information in assisting the practitioners in making clinical decisions (Jiang F, Jiang Y, Zhi H, 2017). For instance, in 
emergency medical services, the AI algorithm has been proven to surpass the conventional triage tools and early warning scores in 
determining patients’ need for critical care (Meskó, 2020). A crucial aspect of healthcare delivery, which is the diagnosis and treatment 
Mohd Shith Putera, N.S.F, et.al., AicQoL2021, AMER International Conference on Quality of Life, Colmar Tropicale, Bukit Tinggi, Malaysia, 17-18 Mar 2021, E-BPJ, 6(16), Mar 2021 (pp.137-144) 
138 
of diseases, has long been a focus of AI since the 1970s (Davenport & Kalakota, 2019). More recently, as it improves, IBM Watson, 
among the pioneer AI systems, has been used in designing treatment plans for patients. With the advent of this AI-integrated systems, 
the process of determining patient treatment pathways which traditionally takes days to complete has now been able to be sped up to 
just a few minutes (Meskó, 2020). 
This would be crucial, for example, in tackling diseases which progress rapidly and can cause complications, such as leukaemia. 
With the aid of IBM Watson, the oncologists at Institute of Medical Science, the University of Tokyo in Japan discovered a rare type of 
secondary leukaemia in a patient which eventually led the team to the patient’s life-saving treatment (Otake, 2016). Meanwhile, in 
cancer research conducted by the University of North Carolina School Of Medicine, 99 per cent of IBM Watson treatment 
recommendations were consistent with those suggested by the oncologists. In 30 per cent of these cases, IBM Watson has 
outperformed the oncologists in discovering treatment options not identified by the oncologists due to adaptation based on cancer 
research papers and recent clinical trial not accessible to the oncologists (Lohr, 2016). On the other hand, within radiology, AI also 
performs better than the radiologists in detecting malignant tumours (Savage, 2020). In 2016, the Moorfields Eye Hospital NHS 
Foundation Trust in England announced a joint venture with Google Deepmind Health in ophthalmology. The collaboration has enabled 
the improvement of eye treatment through analysis of retina scans by Deepmind algorithms. As a result, within just thirty seconds, 
diseases such as diabetic retinopathy, glaucoma and age-related macular degeneration can be detected. Another area worth paying 
attention to concerning AI contribution to the healthcare industry is the drug creation aspect. The process which often takes months or 
even years to complete and involve exorbitant costs of up to billions of dollars may be concluded more speedily and cost-effectively with 
the help of AI. A company, Atomwise, while using its AI technology managed to discover two new drugs meant to reduce the infectivity 
of Ebola in just two days (Meskó, 2020). Another example of AI application in healthcare settings points to health monitoring and 
medication management, particularly relevant post-diagnosis and treatment pathways design. Sense.ly’s Molly, a virtual nurse, carries 
out these tasks by providing personalised follow-up care to monitor and manage chronic diseases in between doctor visits. AiCure, on 
the other hand, a smartphone app, uses the same approach in employing AI to keep track of patient adherence to prescriptions (Meskó, 
2020). AI contribution to the healthcare industry is revolutionary, but not without a price. More mundanely, AI has challenged the way 
scientific understanding and validation of medical technologies operate, precisely, within the framework of medical device regulation. 
Instances of AI producing medical recommendations beyond what humans can comprehend, much less to employ, merit a revisit of the 
aptness of the regulatory pathways for AI. This research, thus, aims to advance the discussion as to the feasibility of the prevailing 
medical devices pre-market evaluation under the Malaysian Medical Device Act 2012 for AI. The objective of this research is to improve 
the Malaysian medical device regulation by comprehending the adaptive nature of AI systems which deviate from the conventional 
medical devices. This research also seeks to learn some lessons from the United States approaches in regulating AI for healthcare 
purposes, precisely on the application of the Total Product Life Cycle approach. 
 
 
2.0 Literature Review 
 
2.1 The Medical Device Regulation 
Throughout the product lifecycle of a medical device, regulatory affairs practitioners serve a vital role, guiding pre-market policy, drafting 
regulatory submissions, and ensuring post-market compliance (Shiffman, 2018). AI is labelled with its ability to self-learn from timely 
data it acquires from real-world applications, placing it amongst software as a medical device (SaMD), an evolving field of research and 
development in the medical device regulation (Benjamens et al., 2020). Taken at face value, the regulatory controls aim to safeguard 
the health and safety of patients, consumers and others by ensuring that medical device manufacturers comply with the prescribed 
procedures during design, manufacture and marketing. The safety and performance of medical devices depend on two critical elements 
adopted by the medical device regulation which are the pre-market review and the post market surveillance (World Health Organisation, 
2015). While the former focuses on product control, the latter guarantees that medical devices in use remain to be safe and effective. 
The two critical elements can be better perceived through the Life Span diagram below: 
 
Fig. 1: Common Elements of Medical Device Regulation (World Health Organisation, 2015) 
 
The elements or components for medical device regulation are universally adopted by countries in the world including Malaysia and 
the United States. Arguably, one of the issues that has raised concerns over the use AI-fuelled medical device is that the level of controls 
would depend on the defined risks associated with devices. Plus, an essential aspect of any regulatory control framework is identifying 
an effective way of producing a sustainable set of regulations (Medical Device Authority, 2014). The classification of medical devices in 
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Malaysia is mainly based on the risk associated with the human body vulnerability, the technological design and development of medical 
devices, which take into consideration the intended use, the transient duration of use and also the part of the human body (Medical 
Device Authority, 2014). Under these rules, the actual classification of each device relies on the claims made by the manufacturer and 
on its intended use. While interpreting these rules, it must be stressed that the actual classification of a specific device must be 
considered individually, considering its nature and intended usage. Despite providing the rules of classification for general medical 
devices, insignificant attention is given to the classification of SaMD by the Malaysian Medical Device Authority (MDA), resulting with a 
reliance towards the international risk categorisation framework discussed below. 
 
2.2 Risk Categorisation and Pre-Market Requirements 
The International Medical Device Regulators Forum (IMDRF) Software as a Medical Device Working Group (WG) has released an 
External Link Disclaimer for Software as a Medical Device, a potential risk categorisation framework. Ideally, the recommendations 
provided in this document will help the manufacturers and regulators to define risk categories of Software as a Medical Device more 
specifically based on how the performance of a Software as a Medical Device is used in various healthcare circumstances or conditions 
for healthcare decisions (US Food and Drugs Administration, 2017). The IMDRF also recommends a set of standards to be implemented 
in the SaMD risk categorisation sense (IMDRF Framework for SaMD Risk Categorisation, 2020) which can be extended to AI SaMD. It 
is important to emphasise that the Software as a Medical Device risk categorisation framework External Link Disclaimer has four 
categories (I, II, III, and IV). These categories are based on patient or public health effect levels where reliable information given by the 
Software as a Medical Device to treat or diagnose, drive or advise clinical management is essential and pertinent to prevent death, long- 
term disability or severe other degradation in health, reduce public health (IMDRF SaMD Working Group, 2017). The Level IV category 
is Software as a Medical Device with the highest impact on the patient or public health. Level I is the lowest. As prescribed in the Medical 
Device Act 2012, the pre-market requirements are the Malaysian Medical Device Authority (MDA) process of scientific and regulatory 
review to evaluate the safety and effectiveness of the classes of medical devices before market placement (Medical Device Authority, 
2014). Section 5 of the 2012 Act Act outlines the manufacturer’s responsibility to ensure that a medical device conforms to the defined 
Essential Principle of Safety and Performance (EPSP), that a medical device’s production is certified with the Good Manufacturing 
Practice (GMP) or with any written directives issued by the MDA, and is packaged, labelled and marked in an approved manner. 
Following the verification by the Conformity Assessment Body (CAB) certifying that the conformity assessment is conducted in 
adherence to the requirements under the Act, the MDA in return will register the medical device (Section 7(1)). Likewise, in the United 
States, to ensure circulation and access to safe medical devices within the society, the Food and Drugs Administration (FDA) adopts a 
risk-based three-class scheme in regulating medical devices. The three regulatory classes embedded in the 1976 Medical Device 
Amendment are: class I - low risk; class II - moderate risk; and class III - high risk. The devices will then be controlled differently based 
on factors such as their “intended purpose” and “indication of purpose”. These factors would determine the type of marketing application 
prior to registering the robots with the FDA (Jarow & Baxley, 2015). The “life cycle concept” adopted by FDA is imperative in guaranteeing 
that the medical devices meet the standard of approval required for marketing purposes. This concept comprises all stages of medical 
devices production and use from pre-market requirement, placing of the device in the market until post-market control. Manufacturers 
of non-exempt devices are required to submit to the FDA either a Pre-Market Approval (PMA) application where FDA would either 
outright approve the device, or a Pre-Market Notification where the device would be cleared if it is significantly similar to the predicate 
devices. In arriving at these decisions, the FDA is guided by the risk demonstrated by the device through information and scientific 
evidence submitted by the manufacturer (Kramer et al., 2012). Prior to each submission, the manufacturers are given opportunities to 
engage in discussions with the FDA with regard to the device to support the marketing application. From the literature, an area that has 
raised concern is that hazard identification and safety metrics should be context-specific in the sense that the technical understanding 
of a particular technology is prioritized. Undoubtedly, the pre-market requirements for medical devices applicable to AI facilitates in 
providing certain and a predictable regulatory environment to manufacturers in positioning healthcare devices into the market. However, 
subjecting AI to the medical device regulation results with the generalisation of the governing rules as early as defining AI as a medical 
device. If the medical device regulation appears to be inefficient in assuring safe and effective medical devices, it is quite impractical to 
evaluate whether ‘unfitness’ implies to be unfit for the medical devices largely or AI specifically. For instance, the rising number of 
lawsuits filed against the Intuitive Inc. concerning the defective Da Vinci Surgical System, a predecessor technology to AI, 
notwithstanding adhering to the regulatory requirement required of a medical device outlined by the FDA, questions arise as to whether 
the medical device regulation pertaining class II medical device is unworkable or whether the medical device regulation is insignificant 
to medical robots altogether. This question will certainly bleed into the regulation of AI within the medical device framework. 
 
 
3.0 Methodology 
This research considers its activities to that of a legal-interdisciplinary interest, an approach pivotal to the development of legal arguments 
by obtaining input from other disciplines of knowledge, particularly for this research, the field of Artificial Intelligence and medical device 
framework (Naudé Fourie, 2015). In the context of this research, the doctrinal analysis is employed to synthesise various statutory 
provisions, regulatory principles, interpretive guidelines and framework (Hutchinson & Duncan, 2014) related to Artificial Intelligence in 
the frame of medical device framework. The principal purpose of this method is also explored in elucidating normative critics for the 
formulation of proposals for the future endeavours. As much as this research is concerned, the sources for the doctrinal 
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analysis approach are captured in written sources such as statutory legislation, case law, regulation guideline documents, journal articles 
and reports retrieved from a library-based search. The library-based search was aided by the UiTM Online Public Access Catalog 
(OPAC) system to identify primary data such as the Medical Device Act 2012, the Malaysian Contracts Act 1950, the Consumer 
Protection Act 1999 (herein referred to as CPA), the United States Uniform Commercial Code 1952, the United States Food, Drugs and 
Cosmetic Act 1976 and law cases (Ghapheryc & White, 2012). Whereas the secondary data consisted of journal articles and reports 
were obtained by browsing law databases such as the Malayan Law Journal, the Current Law Journal, HeinOnline and other databases 
namely Springer, ScienceDirect, SAGE, Emerald and others. The doctrinal analysis facilitates in the interpretation and understanding of 
the relationship between different variables adopted by this research namely the pre-market assessment and its application, the AI 
governance features as well as the integration of AI in the medical setting. 
Data analysis approaches adopted by this research include the comparative method and interpretive method. For comparative 
analysis, this research leverages this method in producing suggestions to improve the current legal position on AI as a medical device 
(Nelken, 2016). In general, comparative analysis observes a systematic perusal of rules, procedures, institutions, and implementations 
within single or multiple legal systems based on objective comparative assessments of similarities, differences, and repercussions (Van 
Hoecke, 2016). A jurisdiction is selected as the country comparison for it provides more legal certainty and a better response to a 
particular event (Von Mehren et al. 1988). For this research, the United States is selected as the country comparison given the 
formulation of the research question which emphasises the adequacy of the Malaysian medical device regulation in governing the risk 
that AI posed to the legal system. In this setting, the researchers' prior knowledge of the United States as the first nation to revamp its 
pre-market approval system for AI as medical devices is used as the taxonomy of comparison (Pieters, 2009). Interpretive analysis, on 
the other hand, associates itself with the significance of doctrinal research in formulating legal doctrines through the analysis of legal 
rules. Unlike scientific research of which the validity of the research findings relies heavily on empirical investigation, the process of 
analysis by which doctrines are derived gravitates towards more idiosyncratic and argument-based approaches (Chynoweth, 2006). 
Due to this, the research confides in the definition of ‘medical devices’ to investigate the competency of the legal system in governing 
AI from the lens of the medical device regulation. In doing so, the definition of medical devices stipulated under the Medical Device Act 
2012 is taken in its broader sense to incorporate the function of AI within the medical context; to diagnose, prevent, treat, provide 
information for medical or diagnostic purposes and others. 
 
 
4.0 Findings 
Distinct from its predecessor disruptive technologies, AI intertwines with the legal system significantly that it has amassed well- 
developed areas of scholarly work and doctrinal support. The literature is replete with discourses on AI and law ever since AI is 
immensely developed and embraced, with the volume of discussion descents on the question of conventional liability framework and its 
interwoven effect with the proprietary nature of AI-black box, autonomous trait, self-learning and reinforced learning (Schirmer, 2019) 
(Gonçalves, 2016) (Balkin, 2015). The chorus of discussion has recently transpired into the deliberation of the institutional competencies 
in formulating AI policy and governance (Scherer, 2015). Although enacting general laws on AI is unfeasible, it is timely that lights are 
thrown upon the investigation of AI’s current and likely social impacts, and perhaps smaller changes to appropriate doctrines and laws 
in response to AI’s positive and negative affordances (Calo, 2017). Pertinent to this research is the unfolding concept of ‘adaptive’ AI 
software as medical devices (SaMD) – where the algorithm learns and improves by itself based on new inputs it acquires during real- 
world use and experience (U. S. Food and Drug Administration, 2019). Self-adaptative software is pivotal in addressing the dynamic 
and robustness of human environment, the complexities of managing unexpected conditions, the heterogeneity level of software 
components as well as the manifold changes of software context, goals and constraints during operation time (Salehie & Tahvildari, 
2009) (Cheng et al., 2014). Correspondingly for AI SaMD, the gleaning of more data to train the system enriches its accuracy and 
performance within the already convoluted medical landscape. Thus, continual improvement becomes an integral part of the attraction 
of Machine Learning in creating components of AI systems that read sensor data, text streams, and then adapt the overall behaviour of 
the AI system accordingly (Bharath, 2019). Nevertheless, since the law is imbued with clarity and precision, the prevalent enthusiasm 
and dynamism regarding the development of adaptive AI in healthcare are seemingly conflicting. In this setting, scientific understanding 
and clinical validation are construed as the fundamentals of the medical device regulation in ensuring the safety and efficacy of medical 
technologies (Pesapane et al., 2018). Unfortunately, adaptive AI SaMD renders these two pillars impracticality. As mentioned before, 
AI SaMD departs from the typical SaMD with its ability to continuously learn, where the adaptation or change to the algorithm materialises 
after the system is distributed for use and has acquired real-world experience (Dwivedi et al., 2019). 
Following the market distribution, the output derived from this learning and adaptive AI algorithm may deviate from the output initially 
approved for a predetermined set of application (Kohli et al., 2019) and thus, potentially more risks and less certainty over their benefits. 
Variance is contributed by software’s susceptibility to the interaction with their environment and organisational aspects such as 
resources, staffing, skills, training, culture, workflow and processes (Gerke et al., 2020). This is further aggravated with AI proprietary 
black-box; the ability of the system to imitate or produce better decision-making than its human counterparts but without being able to 
communicate its reasons for doing so, consequently interfering with the scientific understanding required for market clearance (Price, 
2017). Clinical validation, on the other hand, verifies that clinically meaningful SaMD output for the predefined use, target health care 
population and condition recognised in the SaMD definition statement is yielded. Clinically meaningful in this sense signifies that SaMD 
positive impacts are measurable, patient-centric, and particularly relative to the intended use of AI SaMD for targeted individuals and 
public health (IMDRF SaMD Working Group, 2017). Every clinical application involves a comprehensive clinical validation to be adopted 
by the professional clinical community for use in patient care, such as diagnostics or treatment decisions and must be endorsed by 
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regulatory authorities. Clinical trials require that the accuracy of the developed AI solution is demonstrated against the clinical standard. 
The arguments for clinical validation for AI are twofold; 1) the ability of AI SaMD to produce highly personalised treatment predictions or 
suggestions beyond the artificial testing challenges the clinical validation approaches for medical devices and 2) the diversified standards 
in ensuring the safety and efficacy of AI SaMD. The first argument reflects the increased variance of AI SaMD because of interacting 
with physicians and patients progressively, thus possibly allowing the system to recommend more personalised medical outcomes 
(Gerke et al., 2020). On the other hand, the second argument calls for the accuracy and safety of AI SaMD to be demonstrated against 
the established clinical standard. However, AI SaMD being at the intersection of interdisciplinary fields of information technology (IT), 
medical and Artificial Intelligence carries particular certification baggage precisely on the requirement that the development of the device 
was carried out in conformance with abundant quality standards (Higgins, 2020). Malaysia, in this context, recognised a set of standards 
to ensure a safe and effective passage of medical devices. Development of or verification for mandatory standards specifically for AI is 
however absent. It is also uncertain whether the excellent performance of an algorithm is satisfactory if the solution is a "black box" and 
not transparent and reasonably explainable. In embracing the novel risks posed by AI, it can be presumed that the Malaysian medical 
device regulation undergone a stagnant development as to the applicability of its pre-market and post-market requirements. There is 
scarce literature to support the initiatives taken by the Medical Device Authority in revisiting the existing regulatory pathways, probably 
due to the infant stage of AI adoption in the Malaysian healthcare sector. The United States medical device regulation on the other hand, 
admittedly, has sustained an extensive development and review of its market approval processes to accommodate emerging 
technologies in the healthcare sector. Traditionally, the pre-market review pathway outlined by the FDA comprises of the pre-market 
clearance (510(k), De Novo classification or the Pre-Market Approval depending on the risk that a device demonstrates. However, the 
FDA presumed that the conventional paradigm of regulating medical devices was not formulated for adaptive AI. That said, under the 
operating approach to software modifications, a rerun of the pre-market review is called for as many of these AI software are making 
changes to a device. In 2019, the FDA introduced Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning 
(AI/ML)-Based Software as a Medical Device, describing FDA’s redesigned approaches for AI-related pre-market review, addressing 
the risk of modifications produced by the technology. The models termed in the regulatory proposal empower practices from FDA’s 
existing pre-market programs and grounded on IMDRF’s risk categorization principles, the benefit-risk framework, risk management 
principles outlined in the software modifications guidance and ultimately, the FDA’s organization-based total product lifecycle approach. 
In light of this framework, FDA envisages a “Predetermined Change Control Plan” embedded in every pre-market submission. This plan 
delineates the types of anticipated modifications (referred to as the “Software as a Medical Device Pre-Specifications”) and the related 
methodology being employed to implement those changes in a controlled manner that eventually mitigates risks to patients —referred 
to as the “Algorithm Change Protocol.” 
 
 
5.0 Discussion 
The conformity assessment under the purview of the Malaysian Medical Device Act 2012 is bound by a two-tier evaluation process by 
the CAB and the MDA. The MDA acting conjointly with the CAB is mandated with vast power relating to the design of requirements, 
varying, or revoking conditions of medical device registration. In this respect, the power given mirrors the United States Food and Drugs 
Administration (FDA)'s broad jurisdiction to modify medical device regulatory controls, impelling the market clearance procedures to be 
inconsistent and unpredictable. Adversely, the deployment of innovative medical technologies is delayed (Nurus Sakinatul Fikriah et al., 
2015). As such, the certainty of market approval and deployment of AI SaMD ought to hail from the deep perception and understanding 
of the mechanics of medical device regulation, AI and Machine Learning model methodologies and statistical risk evaluation. Higgins 
(2020) formulated the AI SaMD Regulatory Top-Down Template (as shown in Table 1 below) to determine the audit matrix of AI SaMD. 
In his proposed guidelines, Higgins acknowledged that while AI SaMD is presumed to demonstrate an initial base performance, 
modifying its performance parameters based on the input it accumulates is crucial. In this case, regulatory controls should reflect the 
bounds for the system learning process and strengthened monitoring procedures. This presupposition paralleled the FDA recently 
introduced Regulatory Framework for Modifications to Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical 
Device, depicting the FDA groundwork for a potential approach to pre-market review for AI-based SaMD discussed before. The initiative 
introduced the Total Product Life Cycle regulatory approach by incorporating the FDA benefit-risk framework and risk management 
principles outlined in the software modifications guidance explicitly addressing the adaptive nature of AI (Minssen et al., 2020). 
 
Table 1: AI SaMD Regulatory Top-Down Template (Higgins, 2020) 
Macro Task Sub-Task Details 
Data curation Data acquisition  
 Data storage  
 Data labelling  
Adaptation and Modification Safe bounds on learning 
performance 
Minimal quality must be 
guaranteed. 
 Appropriate performance / input 
monitoring modules 
Existence of a non-adaptive performance 
monitor. 
Robustness analysis of the 
non-adaptive performance 
monitor. 
In-sample performance Basic performance metrics Performance metrics on 
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6.0 Conclusion and Recommendations 
Adaptive AI SaMD transforms the way regulators understand the evaluation of safety and efficacy of medical technologies, from which 
regulatory pathways are formulated. The concept of adaptive AI SaMD against the scientific validation-oriented regulation is brought to 
light, built upon the premise that the traditional medical device regulation is not designed to address the dynamics of adaptive AI SaMD. 
This research has highlighted the inadequacy of the pre-market requirements in the Malaysian medical device regulation to govern AI. 
The premise is grounded on the inability of the existing regulation to appropriately classify AI systems based on its adaptive risks, 
causing incompatible conformity assessments to be applied in assuring its safety and effectiveness. While the medical device regulation 
reflects best practices currently employed to facilitate the regulation of medical software, the differences and gaps pertaining AI systems 
will have to be addressed. In this context, the key to a refined regulation for AI is to produce real world clinical evidence for AI throughout 
its life cycle, and the possibility for additional clinical evidence to support adaptive systems. From the findings of this research, it is 
indicated that an all-inclusive conformity assessment for AI SaMD must be a translation of effective communication between medical 
device regulators and AI experts. Therefore, the design of a regulatory framework should manifest considerations to AI model 
development and methodologies without discounting the rudimentary quality management system. This research contributes to shed 
light on the compatibility of the conformity assessment in the Malaysian pre-market requirements for the adaptive nature of AI and serves 
as a cornerstone to redesign the potential pre-market approach for adaptive AI in Malaysia. It is hoped that future research will shed 
light on the triangulation between the doctrinal analysis as well as the contribution from empirical work, precisely on securing AI providers 
feedback as to the development of a comprehensive regulatory matrix for AI. Additionally, more investigations can be conducted to 
address other audit matrixes of AI SaMD such as data curation, in-sample performance, post-market planning. This, in turn, facilitates 
massive development and integration of cutting-edge medical technologies in the Malaysian healthcare landscape through a defined 
regulatory environment. 
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Paper Contribution to Related Field of Study 
This research contributes to the chorus of legal interdisciplinary research involving Artificial Intelligence and regulatory science of 
medical devices. 
 
 
 
 
  hold-out set. 
Multi-fold cross-validation 
performance. 
Calibration (e.g. comparison 
with clinical trial data). 
 Algorithm properties 
perspective 
Sufficiency of the data set. 
Sufficiency of the data at the 
clinically relevant changeover 
points. 
Hyperparameter tuning 
procedures. 
Expected performance on 
‘similar’ data (in-distribution). 
 Data properties perspective Handling of input 
representations. 
Discontinuities. 
Missing data, data imputation. 
Is convergence assumption 
realistic for non-Gaussian 
data? 
Safe failure modes. 
Post-Market planning Shifting clinical standards / 
Non-stationarity of data 
inputs over time 
Semantic drift. 
New diagnoses. 
New input fields. 
 Surveillance Telemetry streaming 
Paper-based methods. 
 Software updates Certification. 
Deployment. 
                                                                                                   Security/threat model  
Mohd Shith Putera, N.S.F, et.al., AicQoL2021, AMER International Conference on Quality of Life, Colmar Tropicale, Bukit Tinggi, Malaysia, 17-18 Mar 2021, E-BPJ, 6(16), Mar 2021 (pp.137-144) 
 
143 
References 
 
Balkin, J. M. (2015). The Path of Robotics Law. California Law Review. 45-60 
 
Benjamens, S., Dhunnoo, P., & Meskó, B. (2020). The state of artificial intelligence-based FDA-approved medical devices and algorithms: an online database. NPJ Digital 
Medicine, 3(1), 1–8. https://doi.org/10.1038/s41746-020-00324-0 
 
Bharath, A. (2019). Recent advancements in AI – implications for medical device technology and certification. 1–21. https://www.bsigroup.com/en-GB/medical-
devices/resources/whitepapers/downloads/ 
 
Calo, R. (2017). Artificial Intelligence Policy: A Primer and Roadmap. UCDL Review. 399-434. 
 
Cheng, B. H. C., De Lemos, R., Giese, H., Inverardi, P., Magee, J., Andersson, J., Becker, B., Bencomo, N., Brun, Y., Cukic, B., Di Marzo Serugendo, G., Dustdar, S., 
Finkelstein, A., Gacek, C., Geihs, K., Grassi, V., Karsai, G., Kienle, H. M., Kramer, J., … Whittle, J. (2014). Software engineering for self-adaptive systems: A research 
roadmap. Lecture Notes in Computer Science (Including Subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 1-26 
https://doi.org/10.1007/978-3-642-02161-9_1 
 
Chynoweth, P. (2006). Legal Research. 63–71. 
 
Davenport, T., & Kalakota, R. (2019). DIGITAL TECHNOLOGY The potential for artificial intelligence in healthcare. In Future Healthcare Journal (Vol. 6, Issue 2). 94-98. 
 
Dwivedi, Y. K., Hughes, L., Ismagilova, E., Aarts, G., Coombs, C., Crick, T., Duan, Y., Dwivedi, R., Edwards, J., Eirug, A., Galanos, V., 
Ilavarasan, P. V., Janssen, M., Jones, P., Kar, A. K., Kizgin, H., Kronemann, B., Lal, B., Lucini, B., … Williams, M. D. (2019). Artificial Intelligence (AI): Multidisciplinary 
perspectives on emerging challenges, opportunities, and agenda for research, practice and policy. International Journal of Information Management, July, 0–1. 
https://doi.org/10.1016/j.ijinfomgt.2019.08.002 
 
Gerke, S., Babic, B., Evgeniou, T., & Cohen, I. G. (2020). The need for a system view to regulate artificial intelligence/machine learning-based software as medical device. 
Npj Digital Medicine, 3(1), 1–4. https://doi.org/10.1038/s41746-020-0262-2 
 
Ghapheryc, J., & White, E. (2012). Library use of web-based research guides. In Information Technology and Libraries. 21-31 https://doi.org/10.6017/ital.v31i1.1830 
 
Gonçalves, M. A. (2016). Liability Arising from the Use of Artificial Intelligence for the Purposes of Medical Diagnosis and Choice of Treatment: Who Should be Held 
Liable in the Event of Damage to Health? 1-75. 
 
Higgins, D. (2020). On Regulating AI in Medical Products (OnRAMP). ArXiv: Computers and Society. 1-23 http://arxiv.org/abs/2010.07038 
 
Hutchinson, T., & Duncan, N. (2014). Defining and Describing What We Do: Doctrinal Legal Research. 1(1988). 
 
IMDRF SaMD Working Group. (2017). Software as a Medical Device (SaMD): Clinical Evaluation. International Medical Device Regulators Forum, September, 4–8. 
 
Jarow, J. P., & Baxley, J. H. (2015). Medical devices: US medical device regulation. In Urologic Oncology: Seminars and Original Investigations. 
https://doi.org/10.1016/j.urolonc.2014.10.004 
 
Jiang F, Jiang Y, Zhi H, et al. (2017). Artificial intelligence in healthcare: past, present and future. Stroke and Vascular Neurology. 
230-243 .https://doi.org/10.1136/svn-2017-000101 
 
Kramer, D. B., Xu, S., & Kesselheim, A. S. (2012). How does medical device regulation perform in the United States and the European union? A systematic review. In 
PLoS Medicine. https://doi.org/10.1371/journal.pmed.1001276 
 
Lohr, S. (2016). IBM Is Counting on Its Bet on Watson, and Paying Big Money for It - The New York Times. 
 
Medical Device Authority. (2014). Conformity Assessments. 2014. https://portal.mda.gov.my/industry/medical-device- registration/general-medical-device.html#Regulate 
 
Meskó, B. (2020). OPEN A short guide for medical professionals in the era of arti fi cial intelligence. Npj Digital Medicine. 1-8. https://doi.org/10.1038/s41746-020-00333-
z 
Minssen, T., Gerke, S., Aboy, M., Price, N., & Cohen, G. (2020). Regulatory responses to medical machine learning. Journal of Law and the Biosciences. 1-18. 
https://doi.org/10.1093/jlb/lsaa002 
 
Naudé Fourie, A. (2015). Expounding the Place of Legal Doctrinal Methods in Legal-Interdisciplinary Research. Erasmus Law Review. https://doi.org/10.5553/elr.000045 
 
Nelken, D. (2016). Comparative Legal Research and Legal Culture: Facts, Approaches, and Values. In Annual Review of Law and Social Science. 
https://doi.org/10.1146/annurev-lawsocsci-110615-084950 
 
Nurus Sakinatul Fikriah, M. S. P., Hartini, S., & Zulhabri, I. (2015). The Medical Device Regulation for Humanoid Robotics: Does One Size Fits All? Procedia Computer 
Science, 76(December), 381–387. https://doi.org/10.1016/j.procs.2015.12.313 
 
Otake, T. (2016). IBM big data used for rapid diagnosis of rare leukemia case in Japan | The Japan Times. 
 
Pesapane, F., Volonté, C., Codari, M., & Sardanelli, F. (2018). Artificial intelligence as a medical device in radiology: ethical and regulatory issues in Europe and the 
United States. In Insights into Imaging. 745-753 https://doi.org/10.1007/s13244-018-0645-y 
 
Pieters, D. (2009). Functions of comparative law and practical methodology of comparing. Research Master in Law., 1–35. Price, W. N. (2017). Regulating black-box 
medicine. Michigan Law Review. 420-474. 
 
Mohd Shith Putera, N.S.F, et.al., AicQoL2021, AMER International Conference on Quality of Life, Colmar Tropicale, Bukit Tinggi, Malaysia, 17-18 Mar 2021, E-BPJ, 6(16), Mar 2021 (pp.137-144) 
144 
Salehie, M., & Tahvildari, L. (2009). Self-adaptive software: Landscape and research challenges. ACM Transactions on Autonomous and Adaptive Systems, 4(2), 1–40. 
https://doi.org/10.1145/1516533.1516538 
 
Savage, N. (2020). How AI is improving cancer diagnostics. In Nature (Vol. 579, Issue 7800, pp. S14–S16). NLM (Medline). https://doi.org/10.1038/d41586-020-00847-2 
 
Scherer, M. U. (2015). Regulating Artificial Intelligence Systems: Risks, Challenges, Competencies, and Strategies. SSRN Electronic Journal, 29(2). 
https://doi.org/10.2139/ssrn.2609777 
 
Schirmer, J. E. (2019). Artificial intelligence and legal personality: Introducing “Teilrechtsfähigkeit”: A partial legal status made in 
  
Germany. In Regulating Artificial Intelligence. https://doi.org/10.1007/978-3-030-32361-5_6 Shiffman, J. (2018). The Critical Role of Regulatory Affairs in the Medical 
Device Industry. 2018. https://www.northeastern.edu/graduate/blog/regulatory-affairs-in-medical-device-industry/ 
 
U. S. Food and Drug Administration. (2019). Artificial Intelligence and Machine Learning in Software as a Medical Device | FDA. https://www.fda.gov/medical-
devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software- medical-device 
 
US Food and Drugs Administration. (2017). Global Approach to Software as a Medical Device. 2017. https://www.fda.gov/medical- devices/software-medical-device-
samd/global-approach-software-medical-device 
 
Van Hoecke, M. (2016). Methodology of Comparative Legal Research. Law and Method, June 2015. https://doi.org/10.5553/rem/.000010 
 
von Mehren, A. T., Weir, T., Zweigert, K., & Kotz, H. (1988). An Introduction to Comparative Law. The American Journal of Comparative Law. 495-497. 
https://doi.org/10.2307/840281 
 
World Health Organisation. (2015). Medical Device Regulation: Global Overview and Guiding Principles (Vol. 5, Issue July 2013). 
 
